Last reviewed · How we verify
Intraocular Instillation Solution
At a glance
| Generic name | Intraocular Instillation Solution |
|---|---|
| Also known as | Intracameral |
| Sponsor | Federal University of São Paulo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution (PHASE2)
- Mydriatic Drops After Combined Surgery (NA)
- Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis (PHASE4)
- Effect of Topical Dexmedetomidine on Intraocular Pressure (PHASE4)
- Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers (PHASE1)
- The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema (NA)
- Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination (PHASE2)
- Adherence Assessment With Travalert Dosing Aid (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intraocular Instillation Solution CI brief — competitive landscape report
- Intraocular Instillation Solution updates RSS · CI watch RSS
- Federal University of São Paulo portfolio CI